What are the components of Ryzodeg (insulin degludec and insulin aspart)?

From the Guidelines

Ryzodeg is a combination insulin medication that contains two active components: insulin degludec and insulin aspart. The standard formulation of Ryzodeg contains 70% insulin degludec and 30% insulin aspart, allowing for both basal coverage and mealtime control with a single injection, making it convenient for patients with diabetes who require both types of insulin. Some key points to consider about Ryzodeg include:

• Insulin degludec is a long-acting basal insulin that provides a steady background level of insulin for up to 42 hours, while insulin aspart is a rapid-acting insulin that works quickly to lower blood sugar after meals.
• The dual-action nature of Ryzodeg helps maintain blood glucose control throughout the day and specifically during mealtimes.
• Ryzodeg is typically administered once or twice daily with main meals, and the dosage is individualized based on the patient's specific needs, blood glucose levels, and response to insulin therapy, as discussed in the 2024 standards of care in diabetes 1.
• The combination of basal insulin and rapid-acting insulin in Ryzodeg has been shown to be effective in managing blood glucose levels, with a lower risk of hypoglycemia compared to other insulin regimens, as noted in the 2023 standards of care in diabetes 1.

From the FDA Drug Label

The FDA drug label does not answer the question.

From the Research

Components of Ryzodeg

• Ryzodeg is a coformulation of two insulin analogues:
  • Insulin degludec (a ultra-long-acting insulin analogue) 2, 3, 4
  • Insulin aspart (a rapid-acting insulin analogue) 2, 3, 4
• The exact composition of Ryzodeg is 70% insulin degludec and 30% insulin aspart 4

Pharmacological Properties

• The combination of insulin degludec and insulin aspart in Ryzodeg provides both basal and prandial glucose-lowering effects 3, 4
• The pharmacokinetic and pharmacodynamic characteristics of Ryzodeg have been investigated in several clinical studies, demonstrating a flat and stable glucose-lowering profile with a duration of action exceeding 24 hours 3, 4

Clinical Use

• Ryzodeg is used for the management of diabetes mellitus, particularly in patients with type 1 or 2 diabetes who require both basal and prandial insulin coverage 2, 3, 5, 6
• Clinical trials have shown that Ryzodeg can provide effective glycemic control with a lower risk of hypoglycemia compared to other insulin regimens 2, 5, 6